Oruka Therapeutics, Inc. (ORKA) Institutional Ownership

Ownership Summary

A total of 137 institutions have reported a stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) as of December 2025, according to recent 13F filings with the SEC.

• These investors collectively held 93.2% of the company's total shares outstanding in December 2025, up from 82.9% in September 2025.
• In percentage terms, this reflects as a holdings change of 16.78% quarter on quarter, and an increase of 107.58% year over year.
• A review of institutional activity for Oruka Therapeutics shows 96 of 137 filers increasing their positions, while 15 reduced their stake, and 26 remained unchanged.
• This class of investors increased its holdings in Oruka Therapeutics to 51.31Mn shares for the 13F-cycle ending December 2025, up by 7.37Mn shares quarter on quarter, and up 20.36Mn shares year over year.
• FMR LLC continues to be the largest institutional holder of Oruka Therapeutics as of December 31, 2025, with a position of 7.26Mn shares, representing 13.19% of the company's outstanding stock.
• Among the most significant buyers of Oruka Therapeutics during December 2025 were Paradigm Biocapital Advisors LP (1.71Mn), Remedium Capital Partners, LLC (1.55Mn), BlackRock, Inc. (1.33Mn), STATE STREET CORP (731.82K), VANGUARD GROUP INC (676.87K).
• Leading sellers of Oruka Therapeutics stock in December 2025 included BRAIDWELL LP (1.30Mn), Deep Track Capital, LP (493.27K), Point72 Asset Management, L.P. (437.00K), Affinity Asset Advisors, LLC (156.84K), FRANKLIN RESOURCES INC (127.36K).
• The top 10 institutional holders of Oruka Therapeutics for the quarter ending December 2025 included FMR LLC (7.26Mn), VR Adviser, LLC (4.15Mn), Fairmount Funds Management LLC (3.71Mn), BlackRock, Inc. (3.54Mn), VIKING GLOBAL INVESTORS LP (2.67Mn), VANGUARD GROUP INC (2.45Mn), Deep Track Capital, LP (2.16Mn), RTW INVESTMENTS, LP (2.06Mn), Commodore Capital LP (1.75Mn), Paradigm Biocapital Advisors LP (1.71Mn).